-

Coty Launches Scientific Advisory Board on Skincare Innovation

MONACO--(BUSINESS WIRE)--Coty Inc. (NYSE: COTY)(Paris: COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, skin and body care, proudly announces the launch of its first Scientific Advisory Board, following the inaugural meeting on September 24, 2024.

The Advisory Board brings together globally renowned scientific experts from diverse technical disciplines, selected for their unique expertise and contribution to cutting-edge research. The Board will convene twice a year to inform and inspire breakthrough innovations within Coty’s R&D specialists, and therefore strengthen Coty’s efforts to shape the future of skincare.

The first meeting, held at Coty’s Skincare Research & Innovation Center of Excellence in Monaco, brought together these leading scientists to discuss the current themes in skin health and skin repair. The experts provided valuable insights and feedback that will continue to shape Coty’s R&D initiatives and product innovation strategies across all its skincare brands.

Sue Nabi, CEO of Coty, said: “This year marks our 120th anniversary as pioneers in the beauty industry, and I’m honored that such acclaimed scientific minds have agreed to come together to help define the future of Coty skincare as part of our Scientific Advisory Board. Each member has been carefully selected because they are at the forefront of their respective disciplines. Their ongoing insights will play a pivotal role as we continue to collaborate and drive skincare innovation forward for the benefit of all our consumers.”

The Scientific Advisory Board will serve as a forum for the exchange of cutting-edge ideas, innovative thinking, and rigorous challenge. In line with Coty’s commitment to co-creation, the board will align the latest science with emerging trends and consumer needs, which will enhance Coty’s leading position in skin science.

Appropriately, the inaugural meeting of the Scientific Advisory Board took place at Coty’s Center of Excellence in Monaco, where one of the company’s flagship skincare brands was founded 70 years ago.

Members of Coty’s Scientific Advisory Board

Dr. Miriam Merad, MD, PhD – Director of Precision Immunology Institute - New York
Dr. Emma Guttman, MD, PhD – Professor of Dermatology & Immunology - New York
Dr. Patrick Bui, MD – Head of Plastic Surgery Department American Hospital - Paris
Pr. Selim Aractingi, MD, PhD – Team Leader, Cutaneous Biology Labs, Cochin Institute - Paris
Pr. Wei Liu, MD, PhD – Dermatologist - Beijing
Pr. Deng Xingwang – Professor of Life Science - Beijing
Dr. Jaci Santana, MD – Dermatologist - Recife

About Coty Inc.

Founded in Paris in 1904, Coty is one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. We serve consumers around the world, selling prestige and mass market products in more than 125 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and we are committed to protecting the planet. Learn more at coty.com or on LinkedIn and Instagram.

Contacts

Coty Inc.

NYSE:COTY

Release Versions

Contacts

Social Media Profiles
More News From Coty Inc.

Coty Appoints Markus Strobel Executive Chairman and Interim CEO

NEW YORK--(BUSINESS WIRE)--Regulatory News: Coty Inc. (NYSE: COTY) (Paris: COTY) (“Coty” or “the Company”) today announced that Markus Strobel will become Executive Chairman of the Board and Interim Chief Executive Officer, effective January 1, 2026. Strobel joins Coty after a distinguished 33-year career at Procter & Gamble, where he most recently served as President of P&G’s Global Skin & Personal Care business that included a multi-billion-dollar portfolio of more than 12 global...

Coty Sells Remaining Stake in Wella to KKR

NEW YORK--(BUSINESS WIRE)--Regulatory News: Coty Inc. (NYSE: COTY) (Paris: COTY) (“Coty” or “the Company”) today announced that it has sold its remaining 25.8% stake in Wella to KKR managed capital accounts and investment affiliates. Under the terms of the transaction, Coty will receive upfront cash consideration of $750 million and 45% of any proceeds from a further sale or an initial public offering of the business, after KKR’s preferred return has been met. Based on Wella’s strong recent and...

Coty Reports In Line Q1 Results, with Q2 Sales Tracking Toward the More Favorable End of Prior Guidance; Expects a Return to Growth in 2H FY26

NEW YORK--(BUSINESS WIRE)--Regulatory News: Coty Inc. (NYSE: COTY) (Paris: COTY) ("Coty" or "the Company") today announced its results for the first quarter of fiscal year 2026, ended September 30, 2025. Coty delivered Q1 in line with expectations, with Q2 sales tracking toward the more favorable end of prior guidance. Coty's strengthening execution particularly in the U.S. market, combined with strategic initiatives and market-leading fragrance innovations, reinforces the Company’s confidence...
Back to Newsroom